 "Glenmark Pharma Q1 results: Profit falls 86% to ₹47 cr, revenue down 5%")
Glenmark Pharmaceuticals on Thursday reported a steep 86 per cent year-on-year (Y-o-Y) drop in consolidated net profit at ₹46.87 crore for the first quarter of the financial year 2025-26 (Q1FY26), from ₹340.27 crore in the same period last year. However, on a sequential basis, profit skyrocketed from ₹4.65 crore in Q4 F25.
Revenue from operations fell 5.1 per cent Y-o-Y to ₹3,059.33 crore in Q1FY26 from ₹3,223.30 crore in Q1 FY25. Sequentially, too, it declined 5 per cent from ₹3,220.13 crore in Q4FY25.
The company's earnings before interest, taxes, depreciation, and amortisation (Ebitda) stood at ₹580.5 crore, compared to ₹560.7 crore in Q1 FY25, translating into an Ebitda margin of 17.8 per cent.
Overseas markets' revenue subdued
India revenue stood at ₹1,239.9 crore, up 3.7 per cent Y-o-Y from ₹1,196.2 crore, driven by growth in cardiac, respiratory, and dermatology segments despite weakness in diabetes portfolio.
North America revenue stood at ₹778.0 crore, marginally lower than ₹780.8 crore a year ago, but up 8.9 per cent sequentially, driven by injectable and partnered product launches.
Europe revenue came in at ₹667.8 crore, down 4 per cent Y-o-Y from ₹695.7 crore.
“In Q1FY26, our US business delivered Q-o-Q growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25 per cent CAGR and >10 per cent CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards," said Glenn Saldanha, chairman & managing director, of Glenmark Pharmaceuticals.
Shares of Glenmark Pharma closed at ₹2,043.95 apiece on the BSE on Thursday.
Glenmark Pharma Q1 result highlights
- Revenue from operations: ₹3,059.33 crore
- Profit: ₹46.87 crore
- Earnings per share: ₹1.66 (basic and diluted)